SCPH tender offer filing announced; read Schedule TO and 14D-9 for terms

Rhea-AI Filing Summary

The communication states that scPharmaceuticals has initiated a tender offer process and that a Schedule 14D-9 will be filed with the SEC. The offer to purchase scPharmaceuticals common stock will be made only through the formal offer documents filed as part of the Schedule TO, including the offer to purchase and letter of transmittal, and investors are urged to read the tender offer statement and any solicitation/recommendation statement when available. It warns that forward-looking statements involve risks, including integration risks from acquisitions, development and clinical trial timing risks, uncertain milestone payments tied to a contingent value right, and potential adverse effects on Parent's share price if expected benefits are not realized. The filing points readers to www.sec.gov and scPharmaceuticals' Investor Relations page for free copies of related documents.

Positive

• Formal process initiated: A Schedule 14D-9 will be filed and the offer will be made only through documented Schedule TO materials, ensuring regulatory disclosure.
• Access to documents: Investors may obtain free copies of tender offer and solicitation statements from the SEC website or scPharmaceuticals' Investor Relations page.

Negative

• Unspecified economic terms: The communication does not disclose the offer consideration or transaction economics, preventing valuation assessment.
• Contingent milestone risk: Milestone payments tied to a contingent value right may never be achieved, meaning shareholders might receive no additional payments.
• Integration and development risks: The notice highlights risks that acquisitions may not integrate successfully and that clinical or development delays could affect outcomes and valuation.
• Market risk for Parent: If expected benefits are not realized, the market price of Parent's shares could decline.

Insights

M&A Specialist

TL;DR: Tender offer initiated; investors should review formal Schedule TO/14D-9 documents for terms and contingent milestone risks.

The notice is procedural but material: it confirms a tender offer process requiring formal documents that will govern the transaction terms. Key investor implications include dependence on contingent milestone payments and integration execution risk, which can materially affect value transferred to shareholders and the acquiring Parent's shares. Absence of specific economic terms in this text limits valuation assessment; the forthcoming Schedule TO and Schedule 14D-9 will be essential for assessing consideration, timing, and conditions.

Securities Risk Analyst

TL;DR: Forward-looking risks highlighted; document urges reliance on formal SEC filings for authoritative information.

This communication emphasizes standard forward-looking disclaimers and points to SEC filings for definitive details. Material risks called out include clinical-development delays, acquisition integration difficulties, and the possibility that contingent value right milestones are never met, any of which could reduce realized transaction value or affect Parent's market price. Because the notice lacks transaction economics and timing, it is informational but not sufficient to gauge investor impact beyond risk awareness.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO

Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

scPharmaceuticals Inc.

(Name of Subject Company (Issuer))

Seacoast Merger Sub, Inc.

(Offeror)

an indirect wholly owned subsidiary of

MannKind Corporation

(Parent of Offeror)

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

810648105

(CUSIP Number of Class of Securities)

Michael E. Castagna

Chief Executive Officer

MannKind Corporation

1 Casper Street

Danbury, Connecticut 06810

(818) 661-5000

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

With a copy to:

Barbara Borden

Rowook Park

Cooley LLP

10265 Science Center Drive

San Diego, California 92121

(858) 550-6000

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒  third-party tender offer subject to Rule 14d-1.

☐  issuer tender offer subject to Rule 13e-4.

☐  going-private transaction subject to Rule 13e-3.

☐  amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

The pre-commencement communications filed under cover of this Tender Offer Statement on Schedule TO are being filed by MannKind Corporation, a Delaware corporation (“Parent”) and Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), pursuant to General Instruction D to Schedule TO related to a planned tender offer by Purchaser for all of the outstanding shares of common stock, par value $0.0001 per share, of scPharmaceuticals Inc., a Delaware corporation (“scPharmaceuticals”). The planned tender offer will be made pursuant to an Agreement and Plan of Merger, dated as of August 24, 2025 (the “Merger Agreement”), by and among scPharmaceuticals, Parent and Purchaser.

Additional Information about the Transaction and Where to Find It

The tender offer described in this communication (the “Offer”) has not yet commenced, and this communication is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of scPharmaceuticals or any other securities. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the U.S. Securities and Exchange Commission (“SEC”) by Parent and Purchaser, and a Solicitation/Recommendation Statement on Schedule 14D-9 will be filed with the SEC by scPharmaceuticals. The offer to purchase shares of scPharmaceuticals common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which will be named in the tender offer statement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by scPharmaceuticals under the “Investor Relations” section of scPharmaceuticals’ website at www.scPharmaceuticals.com.

Forward-Looking Statements

This communication contains forward-looking statements. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These forward-looking statements include, without limitation, statements related to the anticipated consummation of the acquisition of scPharmaceuticals and the expected timing thereof; the expected benefits from the transaction, including adding a new high-growth revenue stream and a diversified revenue base, accelerating double-digit revenue growth, the potential to expand market reach in the U.S. and globally, providing a meaningful opportunity to unlock growth for both FUROSCIX and Parent’s existing commercial portfolio, strengthening Parent’s commercial portfolio, infrastructure and long-term sustainability, the potential synergies, positioning Parent for sustained growth across cardiometabolic and chronic care markets and to deliver sustained value for its employees and stockholders, enhancing scale and efficiency, reducing fixed costs and improving agility, increasing strategic optionality making Parent more attractive to employees, partners, investors, and a broader healthcare ecosystem; Parent’s strategy and plans for the combined company; integration plans, including with respect to scPharmaceuticals’ employees; the belief that Parent is uniquely positioned to scale FUROSCIX and unlock its full market potential in the future; the estimated aggregate repayment and buyout amount to repay and extinguish all outstanding indebtedness of scPharmaceuticals under its credit facility with Perceptive and buy-out Perceptive’s rights to receive revenue payments pursuant to its revenue purchase and sale agreement upon the closing of the transaction; the potential benefits and market opportunity for FUROSCIX; the potential approval of the FUROSCIX Autoinjector and its potential to enhance FUROSCIX’s market potential and reduce COGS; the planned regulatory filings for the FUROSCIX Autoinjector and the timing thereof; the estimated revenue potential for Tyvaso DPI, Alfrezza, FUROSCIX, Inhaled Clofazimine and Nintedanib DPI; Afrezza being positioned for continued growth; Parent’s ongoing and planned clinical trials, including the Phase 3 trial of Inhaled Clofazimine and the planned Phase 2 trial of Nintedanib DPI in IPF; and

other statements that are not historical facts. These forward-looking statements are based on Parent’s and scPharmaceuticals’ current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Parent’s ability to complete the transaction on the proposed terms and schedule, or at all; whether the various conditions to the consummation of the transaction under the merger agreement will be satisfied or waived; whether stockholders of scPharmaceuticals tender sufficient shares in the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; risks related to Parent’s ability to meet the conditions to draw down the funding from the Blackstone credit facility to fund the transaction; the outcome of legal proceedings that may be instituted against Parent, scPharmaceuticals and/or others relating to the transaction and the risk that such legal proceedings may result in significant costs of defense, indemnification and liability; the failure (or delay) to receive the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the risk that Parent will not be able to retain the employees of scPharmaceuticals following the closing of the transaction given the at-will nature of their employment; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks related to future opportunities and plans for scPharmaceuticals and its products and product candidates, including uncertainty of the expected financial performance of scPharmaceuticals and its products and product candidates and the possibility that the milestone payments related to the contingent value right will never be achieved and that no milestone payment may be made; the possibility that if scPharmaceuticals does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of Parent’s shares could decline; as well as other risks related to Parent’s and scPharmaceuticals’ businesses detailed from time-to-time under the caption “Risk Factors” and elsewhere in Parent’s and scPharmaceuticals’ respective SEC filings and reports, including their respective Annual Reports on Form 10-K for the year ended December 31, 2024 and subsequent quarterly and current reports filed with the SEC. Parent and scPharmaceuticals undertake no duty or obligation to update any forward-looking statements contained in this communication as a result of new information, future events or changes in their expectations, except as required by law.

Item 12. Exhibits

Exhibit No.		Description
(a)(5)(F)		Transcript from MannKind Corporation Investor Call held on August 25, 2025

FAQ

What should SCPH shareholders read before deciding on the tender offer?

Shareholders should read the tender offer statement (Schedule TO) and the solicitation/recommendation statement (Schedule 14D-9) for the full terms and conditions.

Where can I obtain copies of the tender offer and related documents for SCPH?

Copies will be available free at www.sec.gov and via scPharmaceuticals' Investor Relations page at www.scPharmaceuticals.com.

Does this communication guarantee any milestone or contingent payments for SCPH shareholders?

No. The communication explicitly states that the milestone payments related to the contingent value right may never be achieved and no payment may be made.

What are the primary risks mentioned in the SCPH tender offer communication?

Primary risks include acquisition integration difficulties, development and clinical trial delays, and uncertainty of expected financial performance.

Will scPharmaceuticals or Parent update forward-looking statements?

They state they undertake no duty to update forward-looking statements except as required by law.